{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Herreno-Pachon AM"],"funding":["NIH HHS"],"pagination":["4334"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12072265"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(9)"],"pubmed_abstract":["Mucopolysaccharidosis (MPS) IVA is a bone-affecting lysosomal storage disease (LSD) caused by impaired degradation of the glycosaminoglycans (GAGs) keratan sulfate (KS) and chondroitin 6-sulfate (C6S) due to deficient N-acetylgalactosamine-6-sulfatase (GALNS) enzyme activity. Previously, we successfully developed and validated a CRISPR/nCas9-based gene therapy (GT) to insert an expression cassette at the AAVS1 and ROSA26 loci in human MPS IVA fibroblasts and MPS IVA mice, respectively. In this study, we have extended our approach to evaluate the effectiveness of our CRISPR/nCas9-based GT in editing human CD34+ cells to mediate cross-correction of MPS IVA fibroblasts. CD34+ cells were electroporated with the CRISPR/nCas9 system, targeting the AAVS1 locus. The nCas9-mediated on-target donor "],"journal":["International journal of molecular sciences"],"pubmed_title":["CRISPR/nCas9-Edited CD34+ Cells Rescue Mucopolysaccharidosis IVA Fibroblasts Phenotype."],"pmcid":["PMC12072265"],"funding_grant_id":["1R01HD102545-01A1"],"pubmed_authors":["Almeciga-Diaz CJ","Tomatsu S","Herreno-Pachon AM","Leal AF","Khan S"],"additional_accession":[]},"is_claimable":false,"name":"CRISPR/nCas9-Edited CD34+ Cells Rescue Mucopolysaccharidosis IVA Fibroblasts Phenotype.","description":"Mucopolysaccharidosis (MPS) IVA is a bone-affecting lysosomal storage disease (LSD) caused by impaired degradation of the glycosaminoglycans (GAGs) keratan sulfate (KS) and chondroitin 6-sulfate (C6S) due to deficient N-acetylgalactosamine-6-sulfatase (GALNS) enzyme activity. Previously, we successfully developed and validated a CRISPR/nCas9-based gene therapy (GT) to insert an expression cassette at the AAVS1 and ROSA26 loci in human MPS IVA fibroblasts and MPS IVA mice, respectively. In this study, we have extended our approach to evaluate the effectiveness of our CRISPR/nCas9-based GT in editing human CD34+ cells to mediate cross-correction of MPS IVA fibroblasts. CD34+ cells were electroporated with the CRISPR/nCas9 system, targeting the AAVS1 locus. The nCas9-mediated on-target donor ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-04-20T03:22:53.254Z","creation":"2026-04-20T03:14:35.149Z"},"accession":"S-EPMC12072265","cross_references":{"pubmed":["40362571"],"doi":["10.3390/ijms26094334"]}}